We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 24

De-identification and medical records in NSW

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • October 24 2014

Are health service providers in New South Wales obliged by the Health Records and Information Privacy Act 2002 (NSW) to de-identify medical records

Vioxx class action: special leave refused

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • July 10 2012

On 15 May 2012 the High Court refused special leave to appeal from the decision of the Full Federal Court to refuse to award damages in the Vioxx class action

Blockbuster drug goes bust? The Federal Court finds three AstraZeneca patents relating to Crestor (rosuvastatin) invalid

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 7 2013

In an important decision handed down on Tuesday, Justice Jagot of the Federal Court held that three patents relating to the blockbuster drug Crestor

Special leave to appeal refused in the VIOXX class action

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • July 5 2012

The High Court of Australia has refused special leave to appeal from the full court of the Federal Court of Australia in the VIOXX class action

High Court grants special leave to appeal extension of time in pharmaceutical patent case

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • April 15 2014

Last Friday the High Court of Australia granted Alphapharm special leave to appeal from a decision of the Full Federal Court in Aspen Pharma Pty Ltd

Australian case notes - Odisho v Bonazzi 2014 VSCA 11

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • May 20 2014

In this case the appellant, a patient who suffered a thromboembolic event following the use of tranexamic acid, claimed that her doctor had

Federal Court prescribes hard medicine for Vioxx class action

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 15 2012

The full court of the Federal Court of Australia recently overturned a damages award in the VIOXX class action, confirming once again that issues of causation are no less difficult to prove in large-scale class actions than in individual proceedings

Just genes? Lessons from the Myriad litigation

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • August 19 2013

Last month the United States Supreme Court ruled that certain naturally occurring DNA sequences (the BRCA1 and BRCA2 genes, mutations in which are

Pharmaceuticals - copyright in PIs and indirect patent infringement

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • August 4 2011

In the recent decision in Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3), Justice Jagot of the Federal Court found liability for indirect patent infringement in the context of supply of a pharmaceutical product

Competition regulators continue their campaign against pharmaceutical companies

  • King & Wood Mallesons
  • -
  • Australia, USA
  • -
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year